Anti-VEGI (Vascular Endothelial Growth Inhibitor) Antibody
Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, IHC-P, IF, FC |
---|---|
Primary Accession | O95150 |
Other Accession | 241382 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Isotype | Mouse / IgG1, kappa |
Clone Names | VEGI/1283 |
Calculated MW | 28087 Da |
Gene ID | 9966 |
---|---|
Other Names | TNF ligand-related molecule 1 (TL1A); Tumor necrosis factor (ligand) superfamily member 15 (TNFSF15); Vascular endothelial growth inhibitor 192a; Vascular endothelial growth inhibitor (VEGI); VEGI192A |
Application Note | Flow Cytometry (0.5-1ug/million cells in 0.1ml); Immunofluorescence (1-2ug/ml); ,Western Blotting (1-2ug/ml for 60 minutes at RT);,Immunohistology (Formalin-fixed) (1-2ug/ml for 30 minutes at RT),(Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 minutes) ,Optimal dilution for a specific application should be determined. |
Format | 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml. |
Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
Precautions | Anti-VEGI (Vascular Endothelial Growth Inhibitor) Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | TNFSF15 |
---|---|
Synonyms | TL1, VEGI |
Function | Receptor for TNFRSF25 and TNFRSF6B. Mediates activation of NF-kappa-B. Inhibits vascular endothelial growth and angiogenesis (in vitro). Promotes activation of caspases and apoptosis. |
Cellular Location | Membrane; Single-pass type II membrane protein |
Tissue Location | Specifically expressed in endothelial cells. Detected in monocytes, placenta, lung, liver, kidney, skeletal muscle, pancreas, spleen, prostate, small intestine and colon |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
VEGI is an anti-angiogenic cytokine that belongs to tumor necrosis factor superfamily, member 15 (TNFSF15). This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Reduced expression of VEGI has been reported as a marker of poor prognosis in breast cancer.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.